Home Reports Life Sciences Content

Investigational boosted protease inhibitor, TMC114, works better with FUZEON

next article

21.12.2005

Power of ’’FUZEON effect" provides much needed hope for HIV patients facing treatment failure

Exciting interim data presented at the annual ICAAC* conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI), TMC114/r, more than doubles the proportion of patients reaching undetectable levels of the virus.

This latest study provides further evidence that FUZEON now makes undetectable viral loads more achievable for patients failing on their current therapies, when used in combination with the latest HIV drugs. The ’FUZEON effect’ has also been seen in other FUZEON/boosted PI combination trials, including with lopinavir/r and tipranivir/r. This effective strategy for treatment-experienced patients of combining a boosted PI with FUZEON has been recommended by the DHHS guidelines and it is anticipated to revolutionise the management of triple class experienced patients facing HIV resistance.

Interscience Conference on Antimicrobial Agents and Chemotherapy

Sébastien Desprez | Source: EurekAlert!
Further information: www.ketchum.com

next article